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B. SUPPLEMENTAL INFORMATION REGARDING ITEMS IN THE PROPOSED BUDGET FOR THE NEXT PERIOD WHICH 
REQUIRE EXPLANATION OR JUSTIFICATION.(SEE INSTRUCTIONS) 
PERSONNEL--SALARIES 
Salaries that are less than the maximum allowable salaries are requested for 
Dr. Richard Ikeda. The balance of the salary will be paid from institutional support. 
CONSULTANTS 
Dr. Dwight Hall has agreed to voluntarily consult on possible experimental and 
genetic complications that might arise during the project--see the letter in the 
original competitive application. 
TRAVEL 
Domestic travel expenses are requested to allow one researcher to participate 
in one scientific conference per year. 	Participation in conferences will help us 
keep in touch with the current work of other investigators and will provide a forum 
for the critical discussion of our own data. 
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Page 4--SECTION IIA (Continued) 
A significant unobligated balance is estimated in Personnel Salaries and the 
associated Indirect Costs because the grant was funded and first activated during a 
period of previously arranged, temporary, institutional support. Since the FIRST 
grant allows for the carry over of unobligated funds, it was decided that it would be 
easier to leave the institutional support in place and to carry over the unobligated 
balances of the FIRST grant to cover research expenses and summer salary for Dr. 
Ikeda over the lifetime of the 5 year grant. The ability to carry over money to cover 
Dr. Ikeda's summer salary over the lifetime of the grant will permit Dr. Ikeda to 
forego summer teaching assignments and will allow him to devote his full effort to 
this project during the summer. 	It is expected that this will greatly improve the 
productivity of the project. 
This carry-over of funds was done with the implicit understanding that (1) 
FIRST grants were designed to be flexible to cope with the needs of a young research 
group and that (2) the carry over of an unobligated balance under these 
circumstances would not reduce the total budget approved for the grant. 
OTHER SUPPORT 




FOLLOW INSTRUCTIONS CAREFULLY. Incomplete, inaccurate, or ambiguous information about OTHER SUPPORT could lead to delays in 
the award. OTHER SUPPORT to be listed here refers to all current or requested support whether related to this application or not. If there are 
changes subsequent to submission, notify the Grants Management Official named on the Notice of Grant Award. 
For each of the key personnel named on page 4, list, in three separate groups: (1) all currently active support; (2) all applications and 
proposals pending review or funding; and (3) applications and proposals planned or being prepared for submission. Include all Federal, 
non-Federal (e.g., for-profit, pharmaceutical, foundations), and institutional research, training, and other grant, contract, and fellowship support 
at the applicant organization and elsewhere. If part of a larger project, identify the principal investigator/program director and provide the data 
for both the parent project and the subproject. If none, state "none." 
For each item give: (a) the source of support, identifying number and title; (b) percentage of appointment on the project; (c) dates of entire 
project period; (d) annual direct costs; (e) a brief description of the project; (f) whether the item overlaps, duplicates, or is being replaced or 
supplemented by the present application; delineate and justify the nature and extent of any scientific and/or budgetary overlaps or boundaries; 
and (g) any modifications that will be made should this continuation award be made. 
PRINCIPAL INVESTIGATOR/PROGRAM DIRECTOR: 
(1) CURRENTLY ACTIVE SUPPORT: (a) 
I) a. National Institutes of Health, NIAID, 5R29AI24905-02, "The Molecular 
Basis of Function of T7 RNA Polymerase;" b. RAI 50% Effort; 
c. 3/1/89-2/28/94; d. Average Annual Direct Costs = $62,985 per year. 
II) a. National Institutes of Health, Biomedical Research Support Grant, 
RR07024-25, "The Cloning and Expression of Human Serum Transferrin;" b. RAI 10% 
Effort; c. 6/1/90-3/31/91; d. Annual Direct Costs = $3,500. 
III) a. National Institutes of Health, NCI, NO1 - CM-87269. "The Synthesis of 
Cogeners and Prodrugs of Anti-AIDS Compounds;" b. RAI 5% Effort; 
c. 8/1/87-7/31/91; d. Annual Direct Costs = $2,250 (Consultant). 
IV) a. National Science Foundation, DIR-9011409, "Assembly of a Core Facility 
For Biological and Biochemical Research--A Laboratory for Protein/Peptide 
Synthesis, Purification, and Characterization;" b. RAI 5% Effort; c. 7/1/90-12/31/92; 
d. Annual Direct Costs = $217,000 (50% Matching funds provided by Georgia Tech). 
(2) Pending support 
I) a. Alfred P. Sloan Foundation Research Fellowship; b. RAI % Effort--Not 
Applicable; c. 2 years of support requested, submitted Oct. 15, 1989; d. Annual Direct 
Costs = $25,000; e. A grant of unrestricted funds to support the research of young 
investigators. 
Graduate Research Assistant: 	Paul Bailey 
(1) Current Support: None 
(2) Pending Support: None 
Graduate Research Assistant: 	Sakuntala Warshamana 
(1) Current Support: None 
(2) Pending Support: None 
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PRINCIPAL INVESTIGATOR OR PROGRAM DIRECTOR 
Richard A. Ikeda 
APPLICANT ORGANIZATION 
Georgia Tech Research Corporation 
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Molecular Basis of Function of T7 RNA Polymerase 






I. PLANS FOR 1991-1992 
The objectives and specific aims of our studies of T7 RNA polymerase are the 
same as those originally proposed at the time of our competitive review. The long 
term goals continue to be (A) to determine the relationship of structure and function 
in T7 RNA polymerase and (B) to relate structure/function in T7 RNA polymerase to 
the mechanisms for the temporal control of transcription in replicating T7 phage. 
In the next year we plan, to: 
1) Continue our studies of how promoter structure and sequence affect 
promoter strength by examining the formation of specific initiation and 
transcription complexes on T7 class II and class III promoters 
2) Define the active structural domains of T7 RNA polymerase by characterizing 
promoter permissive T7 RNA polymerase mutants and 
3) Characterize how interactions with other proteins might alter transcription 
by T7 RNA polymerase by studying the affect of purified gene product 3.5 on 
initiation, elongation, and termination by T7 RNA polymerase. 
Specifically, during the 1991-1992 funding period we intend to publish our 
measurements of the kinetics of abortive initiation from the T7 class II and class III 
promoters, use footprinting and gel shift assays to identify the transcription 
complexes formed on T7 promoters, measure the efficiency of transcription from the 
natural T7 promoters,. examine and characterize possible promoter permissive 
mutants of T7 RNA polymerase that have been selected by second site reversion, and 
characterize the purified gene product 3.5 that has been produced by recombinant 
methods. The experimental designs and methods to be used to pursue these objectives 
were previously described in the original proposal. 
II. STUDIES CONDUCTED 
During the past year we have made significant progress with our work in the 
three areas mentioned above. 
1) In our studies of how T7 promoter structure and sequence affect promoter 
strength, Ms. Jane Clarke and Ms. An Chi Lin have examined the rate of formation of 
abortive initiation products as a function of promoter concentration. Working with 
the cloned T7 promoter, S10, Ms. Clarke showed that in the presence of ATP and GTP 
promoter dependent RNA synthesis by T7 RNA polymerase gives a 
hexaribonucleotide. Ms. Clarke also demonstrated that this abortive hexamer 
accumulates over time, and that the rate of production of this hexamer can be 
measured as a function of T7 promoter concentration and T7 RNA polymerase 
concentration. As expected, the maximum rate of hexamer synthesis was dependent 
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on RNA polymerase concentration, but the data also showed that the promoter 
concentration that results in half the maximum rate of hexamer synthesis 
(designated as M/2) is independent of RNA polymerase concentration. Ms. Clarke and 
Ms. Lin measured maximum rates of abortive synthesis and M/2 concentrations for 
three cloned class III promoters (4)13, 4)10, and .6.5) and three cloned class II 
promoters ($3.8, $1.3, and $1.1B). The class III promoters are all identical to the 23 
base pair consensus sequence for a T7 promoter, while each of the class II promoters 
differs from the T7 consensus sequence at 3 or 4 bases. Ms. Clarke and Ms. Lin found 
that the maximum rates of abortive synthesis and the M/2 concentrations were 
useful for comparing promoter strengths. The M/2 concentrations showed that on 
supercoiled templates the class II promoters $1.3 and $1.1B acted like the three class 
III promoters, while on linear templates it was clear that the three class H promoters 
were much weaker than the three class III promoters. These observations may 
explain why other investigators see no class differences in cloned T7 promoters in 
vivo, while T7, itself, shows more transcription from class III promoters than class II 
promoters; furthermore, this may suggest that the T7 genome is not negatively 
supercoiled in vivo. 
2) To obtain promoter permissive mutants of T7 RNA polymerase Ms. Sakuntala 
Warshamana has been working on constructing a selection system for identifying 
possible T7 RNA polymerase mutants. 
The selection scheme relies on a two plasmid, T7 expression system. Ms. 
Warshamana has cloned the tet and cat genes under the T7 $10 promoter (pT7-5Tet 
and pT7-5Cat), and has shown that these plasmids stably confer tetracycline 
resistance or chloramphenicol resistance to E. coli harboring and expressing T7 RNA 
polymerase from the gene 1 clone pGP1-5. Once she had shown that the expression 
system was stable and that antibiotic resistance was only expressed in the presence of 
T7 RNA polymerase, Ms. Warshamana replaced the 4)10 promoter in the tet and cat 
plasmids with a synthetic promoter that contained random mutations. 	Inactive 
promoters were then selected from this library of mutants. To date, Ms Warshamana 
has isolated approximately 30 separate clones with inactive promoters. 
To obtain mutants of T7 RNA polymerase, Ms. Warshamana treated the T7 RNA 
polymerase clone with hydroxyl amine to randomly mutagenize the RNA polymerase 
gene. The mutagenized RNA polymerase plasmid and the tet plasmids with inactive 
promoters were then cotransformed into E. coli, and the culture was plated on 
tetracycline selection plates. 	Ms. Warshamana recently identified 5 different 
mutagenized RNA polymerase clones that express tetracycline resistance from 
inactive T7 promoters. Although this is a promising result, we still need to confirm 
that the observed tetracycline resistance is caused by usage of the mutant T7 
promoter by a mutant T7 RNA polymerase. 
3) The T7 3.5 protein (or gp 3.5) has been implicated in the regulation of T7 
transcription. 	The characterization of this interesting protein is a project being 
pursued by Mr. Paul Bailey. To obtain the 3.5 protein, Mr. Bailey has cloned T7 gene 
3.5 behind the inducible lambda promoter p i . In this system, 3.5 protein is the major 
protein produced in E. coli after induction of the lambda promoter. A scheme to 
purify the 3.5 protein has been devised by Mr. Bailey. To purify gp3.5, the protein 
that passes through both DEAE-cellulose and phosphocellulose is collected. This pool 
is then applied to a rotofor and is purified via preparative isoelectric focusing; the 
remaining impurities are then removed on a sephadex column. The procedure yields 
approximately 6 mg of protein from a 3 liter culture. The purity of the protein is 
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greater than 98% and the sequence of the first 30 amino acids of the protein matches 
the sequence predicted from the DNA sequence of the gene. We are presently 
investigating the activity of the purified protein . . 
Not Applicable. 
Not Applicable 
III. HUMAN SUBJECTS 
IV. VERTEBRATE ANIMALS 
V. PUBLICATIONS 





Check the appropriate boxes and provide the information requested. Make this page the last page of the signed original of the application. 
Do not 	copies a( Ills page to the duplicated copies a( the application. 
ASSURANCES 
The following certifications described below are made by checking the appropriate boxes and verified by the signature of the OFFICIAL 
SIGNING FOR APPLICANT ORGANIZATION on the FACE PAGE of the application. 
a. Definquent Federal Debt. 	No 	0 Yes (If "Yes," attach explanation.) 
Before agrant award can be made, the applicant organization must certify that it is not delinquent on the repayment of any Federal debt. 
The certification applies to the applicant organization, not to the person signing the applicationas the authorized representative nor to the 
principal investigator/program director. 
Examples of Federal debt include delinquent taxes, audit disallowances, guaranteed or direct student loans, FHA loans, business loans, and 
other miscellaneous administrative debts. For purposes of this certification, the following definitions of "delinquency" apply: 
• For direct loans and fellowships (whether awarded directly to the applicant by the Federal Government or by an institution using Federal 
funds), a debt more than 31 days past due on a scheduled payment. (Definition excludes "service" payback under a National Research 
Service Award.) 
■ For guaranteed and insured loans, recipients of a loan guaranteed by the Federal Government that the Federal Government has 
repurchased from a lender because the borrower breached the loan agreement and is in default. 
■ For grants, organizations in receipt of a "Notice of Grants Cost Disallowance" which have not repaid the disallowed amount or which 
Erie not resolved the disallowance. (Definition excludes disallowances in an "appeal" status.) 
Where the applicant discloses delinquency on debt to the Federal Government, the PHS shall (1) take such information into account when 
determining whether the prospective grantee organization is responsible with respect to that grant, and (2) consider not making the grant 
until payment is made or satisfactory arrangements are made with the agency to whom the debt is owed. Therefore, it may be necessary 
for the PHS to contact the applicant before a grant can be made to confirm the status of the debt and ascertain the payment arrangements 
for its liquidation. Applicants that fail to liquidate indebtedness to the Federal Government in a businesslike manner place themselves at 
risk of not receiving financial assistance from the PHS. 
b. Debarment and Suspension. 2] 	No 	0 Yes (If "Yes," attach explanation.) 
Before a grant award can be made, the applicant organization must certify, among other things, that neither it nor its principals are presently 
debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from covered transactions by any Federal 
department or agency. Subawardees, that is, other corporations, partnerships, or other legal entities (called "lower tier" participants), must 
make the same certification to the applicant organization concerning their covered transactions. Please refer to the pertinent DHHS 
implementing regulations, Title 45 Code of Federal Regulations Part 76, for complete certification requirements. 
c. Drug-Free Workplace. 	Ei Yes 	❑ No (If "No," attach explanation.) 
Before a grant award can be made, the applicant organization must certify that it will provide a drug-free workplace. The main points of the 
certification require the applicant organization to: 
■ Publish a statement notifying employees that the unlawful manufacture, distribution, dispensation, possession, or use of a controlled 
substance is prohibited in the workplace and specifying the actions that will be taken against employees for violation of such prohibition; 
■ Establish a drug-free awareness program; 
• Require that each employee engaged in the performance of a grant or contract be provided a copy of the published statement; 
• Notify the employee that as a condition of employment, the employee will abide by the terms of the statement; 
• Notify the PHS awarding component of any employee convicted of a drug violation occurring in the workplace; and 
• Require any employee who is convicted of a drug offense occurring in the workplace to participate in a rehabilitation program. 
Please refer to the pertinent DHHS implementing regulations, Title 45 Code of Federal Regulations Part 76, for complete certification 
requirements. 
INDIRECT COST CALCULATION 
Indicate the applicant organization's most recent indirect cost rate established with the appropriate DHHS Regional Office, or, in the case of 
for-profit organizations, the rate established with the appropriate PHS Agency Cost Advisory Office. Indirect costs will not be paid on foreign 
grants, construction grants, grants to Federal organizations and grants to individuals, and usually not on conference grants. Follow any 
additional instructions provided for Research Career Development Awards, Institutional National Research Service Awards, and specialized 
grant applications. 
• DHHS Agreement Dated: 	❑ No Indirect Costs Requested 
Eli No DHHS Agreement, but rates established with Office of Naval Research 	DATE  6/1/90  
• CALCULATION 
Enter proposed budget period: 
Amount of Base $ 64, 499 	x Rate Applied 	62.5 	% 	Indirect Costs S 40,312  
Add to total direct costs from page 2 and enter new total on FACE PAGE, Item 10b 
• Check appropriate box(es) 
O Salary and wage base 	 xi Modified total direct costs base 	El Other base (Attach explanation) 
▪ Ott-site, other special rate, or more than one rate involved (Attach explanation) 
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-With. the • *warding :  of any..federal:oOntrect, the • making of any 
Federal* grant,: the making of any Federal. loan,. *es entering into 
of any cooperative..agreement;. and the •exterisi06:- tOntinuation, 
. renewal,. amendment; :.or modifiCation Of any Fedarel'contract, 
grant, loan, or. dooperatiVe agreement. 
. (2) Sf any. funds other than Federal appropriated funds have been 
paid* or will be paid to 	PersOn for influenting'or . attempting 
• to . influents *-azi officer, or employee of. any agency, a Member of 
Congreeire. :in -officer or 'employee. of Congress,. , or *in employee of a 
Member_ottongrOwin connection with this Federal contract, 
grant, loan,. or cooperative*agreement, the:Undersigned shall 
complete and Subinit Standard Forin-IALL,* *Diiiclosure Form to .Report 
LobbYing," in ,accordance With its instructions. 
(3). The undeksignod shall require that the language of this 
certification .be included to the award dopUments for all 
isubaWards at all tiers (including subtontritotip subwrants, and 
contracts Under grants, *loans, arid cooperative agreements) and 
that all subrecipients shall certify and disolose"accordingly. 
This certification is a material representation of fact upon 
which reliance y 	
. 
es placed whin this tranEaction was made or 
entered 'into.SubmissiOn.eg this certificatOn42:a prerequisite 
for taking or e 
i 
ntering into this' transaction . imposed by section 
1352, title 31, U.S..,. 	Code; -Any parson: who lain to file the 
- .required certification shall :bo 'subject to a civil penalty of not 
less than $10,000 arid not • more than $100, 000 for each such 	' 
failure. 
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